Advertisement

Cambridge small-molecule therapeutics developer Forma Therapeutics Inc. has signed a drug discovery collaboration agreement with Eisai Inc., the U.S. subsidiary of Tokyo pharmaceutical firm Eisai Co. Ltd.

As part of the deal, Forma will receive $20 million in upfront payments and funding from Eisai, as well as future milestone payments and royalties on products developed by Eisai that stem from the Forma collaboration.

SOURCE

Advertisement
Advertisement